Literature DB >> 20234093

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Rupal Ramakrishnan1, Deepak Assudani, Srinivas Nagaraj, Terri Hunter, Hyun-Il Cho, Scott Antonia, Soner Altiok, Esteban Celis, Dmitry I Gabrilovich.   

Abstract

Cancer immunotherapy faces a serious challenge because of low clinical efficacy. Recently, a number of clinical studies have reported the serendipitous finding of high rates of objective clinical response when cancer vaccines are combined with chemotherapy in patients with different types of cancers. However, the mechanism of this phenomenon remains unclear. Here, we tested in mice several cancer vaccines and an adoptive T cell transfer approach to cancer immunotherapy in combination with several widely used chemotherapeutic drugs. We found that chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTLs through a dramatic perforin-independent increase in permeability to GrzB released by the CTLs. This effect was mediated via upregulation of mannose-6-phosphate receptors on the surface of tumor cells and was observed in mouse and human cells. When combined with chemotherapy, CTLs raised against specific antigens were able to induce apoptosis in neighboring tumor cells that did not express those antigens. These data suggest that small numbers of CTLs could mediate a potent antitumor effect when combined with chemotherapy. In addition, these results provide a strong rationale for combining these modalities for the treatment of patients with advanced cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234093      PMCID: PMC2846048          DOI: 10.1172/JCI40269

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation.

Authors:  G van Loo; P Schotte; M van Gurp; H Demol; B Hoorelbeke; K Gevaert; I Rodriguez; A Ruiz-Carrillo; J Vandekerckhove; W Declercq; R Beyaert; P Vandenabeele
Journal:  Cell Death Differ       Date:  2001-12       Impact factor: 15.828

2.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Authors:  D I Gabrilovich; T Ishida; S Nadaf; J E Ohm; D P Carbone
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

3.  Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.

Authors:  M Hilburger Ryan; S I Abrams
Journal:  Cancer Immunol Immunother       Date:  2001-01       Impact factor: 6.968

4.  Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.

Authors:  B Motyka; G Korbutt; M J Pinkoski; J A Heibein; A Caputo; M Hobman; M Barry; I Shostak; T Sawchuk; C F Holmes; J Gauldie; R C Bleackley
Journal:  Cell       Date:  2000-10-27       Impact factor: 41.582

5.  An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53.

Authors:  E Y Nikitina; S Chada; C Muro-Cacho; B Fang; R Zhang; J A Roth; D I Gabrilovich
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

6.  Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.

Authors:  Bin Yu; Sergei Kusmartsev; Fengdong Cheng; Maria Paolini; Yulia Nefedova; Eduardo Sotomayor; Dmitry Gabrilovich
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  Full-length dominant-negative survivin for cancer immunotherapy.

Authors:  Vladimir Pisarev; Bin Yu; Raoul Salup; Simon Sherman; Dario C Altieri; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

8.  Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation.

Authors:  V R Sutton; J E Davis; M Cancilla; R W Johnstone; A A Ruefli; K Sedelies; K A Browne; J A Trapani
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

9.  Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax.

Authors:  J A Heibein; I S Goping; M Barry; M J Pinkoski; G C Shore; D R Green; R C Bleackley
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

10.  A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death.

Authors:  Joseph A Trapani; Vivien R Sutton; Kevin Y T Thia; Yu Qin Li; Christopher J Froelich; David A Jans; Mauro S Sandrin; Kylie A Browne
Journal:  J Cell Biol       Date:  2003-01-21       Impact factor: 10.539

View more
  171 in total

Review 1.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

2.  Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors:  Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

3.  Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system.

Authors:  Metamia Ciampricotti; Cheei-Sing Hau; Chris W Doornebal; Jos Jonkers; Karin E de Visser
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

4.  Targeting dendritic cell metabolism in cancer.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2010-08       Impact factor: 53.440

5.  Chemotherapy. Conventional chemotherapy boosts the effect of cancer vaccines.

Authors:  Lisa Richards
Journal:  Nat Rev Clin Oncol       Date:  2010-06       Impact factor: 66.675

Review 6.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

7.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Xiaojun Qian; Ajay K Gopal; David G Maloney; Catherine G Lindgren; Yukang Lin; John M Pagel; Lihua E Budde; Andrew Raubitschek; Stephen J Forman; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

8.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

Review 9.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

Review 10.  Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.

Authors:  Nathan B Roberts; Aniket S Wadajkar; Jeffrey A Winkles; Eduardo Davila; Anthony J Kim; Graeme F Woodworth
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.